This is a working overview of triple agonist, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-05-22 and is reviewed periodically as new material appears.
Pharmacologically, retatrutide acts as a triple agonist at the glucagon-like peptide-1 receptor, the glucose-dependent insulinotropic polypeptide receptor, and the glucagon receptor. Activation of the first two receptors is associated with improved insulin secretion and reduced appetite. The glucagon receptor component is thought to increase energy expenditure, a mechanism that distinguishes this molecule from dual-agonist compounds. Researchers continue to investigate how the three activities interact and whether the combined profile offers advantages that justify additional clinical testing.
Several questions about the compound remain unresolved. The durability of weight reduction after treatment stops, the frequency of gastrointestinal side effects, and the long-term cardiovascular profile are topics of ongoing study. Regulatory submissions and phase 3 trial outcomes have not been fully reported in the public literature. Because most available data come from controlled trials rather than general-population use, conclusions about effectiveness outside study settings are provisional. The distinction between established findings and open questions matters when interpreting early coverage of the drug.
Retatrutide is an investigational peptide developed by a pharmaceutical company as a multi-receptor agonist for treating obesity and type 2 diabetes. The compound emerged from research into gut-hormone analogues that act on several receptors simultaneously rather than on a single target. Early preclinical work examined how combined activity at three distinct receptors might produce greater metabolic effects than single-receptor compounds. Published phase 2 results have described substantial reductions in body weight among participants, although the compound remains unapproved in most jurisdictions as of the mid-2020s.
临床研究通常测量体重、腰围、空腹血糖、糖化血红蛋白和血脂，并记录不良事件。药代动力学评估关注浓度-时间曲线，药效动力学评估关注代谢标志物变化。体重下降由能量摄入减少、能量消耗变化和脂肪组织重塑共同造成，具体权重仍不明确。研究之间的终点定义和随访时长差异使横向比较复杂。
瑞他鲁肽同时激活GLP-1受体、GIP受体和胰高血糖素受体，这三者均属于B类G蛋白偶联受体。受体激活后主要经cAMP信号通路传递效应。GLP-1成分与食欲抑制和胃排空延缓相关，GIP成分影响脂肪组织与胰岛素分泌，胰高血糖素成分则促进肝糖输出和能量消耗。各受体贡献的相对比例在人体中尚未完全量化。
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Contains non-natural residues |
| Receptor targets | GLP-1, GIP, glucagon | Triple agonist profile |
| Route of administration | Subcutaneous injection | In clinical trial settings |
| Development status | Investigational | Not approved in major markets |
| Approximate molecular mass | About 4.7 kDa | Peptide-scale molecule |
Peptides in this class degrade mainly through hydrolysis, oxidation, and aggregation. The lipid modification improves plasma residence time but can also promote self-association in aqueous solution at higher concentrations. Oxidation of methionine and deamidation of asparagine residues are common chemical liabilities that accumulate during storage. Stability studies therefore track purity loss, aggregate formation, and changes in receptor-binding potency over time under defined temperature and humidity conditions.
Solid peptide is generally held as a lyophilised powder at low temperature to slow degradation, with desiccant to limit moisture uptake. Reconstituted solutions are less stable and are usually kept refrigerated and protected from light for short periods. Repeated freeze-thaw cycles are avoided because they encourage aggregation. Laboratory handling includes work in a fume hood or laminar flow cabinet to limit inhalation and contamination. Weighing and transfer steps are performed with antistatic tools to reduce static-driven loss of fine powder.
As a peptide, the compound is generally supplied as a lyophilized powder and stored frozen to slow degradation. Recommended conditions usually sit at minus twenty degrees Celsius or colder, shielded from light and moisture. Solutions are less stable than the dry powder and are often prepared fresh before analysis. Repeated freeze-thaw cycles can drive aggregation, so splitting stock material into small aliquots reduces handling stress and preserves sample integrity.
Quality control of research material relies on several complementary checks. Purity testing confirms the absence of truncated or oxidized peptide species, while water content and counterion analysis show how much mass comes from salts rather than the peptide itself. Sequence verification through tandem mass spectrometry ensures the correct amino acid chain. Because unregulated suppliers vary widely, independent verification of identity and purity is often necessary before a sample enters experiments.
Development has progressed from single- and multiple-ascending-dose studies in healthy volunteers into larger randomized trials in adults with obesity, type 2 diabetes, and fatty liver disease. Early reports describe dose-dependent reductions in body weight and improvements in glycemic markers over treatment periods of several months. Whether the glucagon arm adds tolerability cost without added benefit is still debated. Long-term cardiovascular outcomes, effects after treatment stops, and performance in older or comorbid populations are open questions rather than settled findings. Approval status may change, so the current investigational label should be confirmed against regulatory sources.
Retatrutide is an investigational synthetic peptide developed under the code LY3437943, with a backbone derived from glucose-dependent insulinotropic polypeptide. Several non-proteinogenic residues, including alpha-aminoisobutyric acid, appear in that backbone, and a fatty diacid side chain attached through a linker extends circulation time. The molecule carries roughly thirty-nine amino acid units and a total mass near 4.7 kilodaltons. Administration is by subcutaneous injection once weekly. Published work uses both the name retatrutide and the code LY3437943.
Solid material is generally held at -20 °C or colder, while reconstituted solutions are kept at 2-8 °C and used within a short window. Buffers that maintain a slightly acidic to neutral pH tend to improve short-term peptide stability. Repeated warming and cooling of stock solutions promotes aggregation and should be avoided. Container closures should remain intact, since adsorption to some plastics can reduce the amount of peptide in solution.
Identity and purity are established with reversed-phase high-performance liquid chromatography and mass spectrometry. Chromatographic profiles reveal related impurities, truncated sequences, and oxidation products, while mass measurement confirms the expected molecular mass. Purity values for research material are typically reported as a percentage by peak area. Reference standards help calibrate retention behavior across instruments. Independent laboratories emphasize method suitability because results depend heavily on column chemistry, gradient, and detection wavelength. Batch-to-batch comparison relies on the same validated method.
Investigational peptide material is commonly distributed as a lyophilized powder in sealed vials. The solid form appears as a white to off-white cake or powder and is hygroscopic once opened. Peptides of this size are sensitive to moisture, repeated freeze-thaw cycles, and prolonged exposure to ambient light. Handling practices therefore emphasize desiccation, minimal vial opening, and cold storage. Working aliquots are often prepared to avoid repeatedly warming the bulk container.
== Synthesis == A number of methods for synthesis have been published. The most recent is probably the method posted by the Serbian chemical society (2004). There is another method, though, for constructing the N-Benzyl-3-methyl-4-piperidone in a 2-stage Michael reaction, followed by Dieckmann cyclization as per usual.
A geographic information system (GIS) can recognize and analyze the spatial relationships that exist within digitally stored spatial data. These topological relationships allow complex spatial modelling and analysis to be performed. Topological relationships between geometric entities traditionally include adjacency (what adjoins what), containment (what encloses what), and proximity (how close something is to something else).
== Modern definitions == In broad metaphorical (colloquial) usage of the term, "poison" may refer to anything deemed harmful. In biology, poisons are substances that can cause death, injury, or harm to organs, tissues, cells, and DNA usually by chemical reactions or other activity on the molecular scale, when an organism is exposed to a sufficient quantity. Medicinal fields (particularly veterinary medicine) and zoology often distinguish poisons from toxins and venoms. Both poisons and venoms are toxins, which are toxicants produced by organisms in nature. The difference between venom and poison is the delivery method of the toxin. Venoms are toxins that are actively delivered by being injected via a bite or sting through a venom apparatus, such as fangs or a stinger, in a process called envenomation, whereas poisons are toxins that are passively delivered by being swallowed, inhaled, or absorbed through the skin. Unantidoteable refers to toxins that cannot be neutralized by modern medical technology, regardless of their type.
Scalephobicity and antifouling Coatings for gas evolution reaction electrodes for efficient bubble detachment Breast implants Contact lenses (silicone hydrogels, polyacrylamides, polymacon) Water sustainability: Hydrogels have emerged as promising materials platforms for solar-powered water purification, water disinfection, and atmospheric water generator. Disposable diapers where they absorb urine, or in sanitary napkins Dressings for healing of burn or other hard-to-heal wounds. Wound gels are excellent for helping to create or maintain a moist environment. EEG and ECG medical electrodes using hydrogels composed of cross-linked polymers (polyethylene oxide, polyAMPS and polyvinylpyrrolidone) Encapsulation of quantum dots Environmentally sensitive hydrogels (also known as 'smart gels' or 'intelligent gels'). These hydrogels have the ability to sense changes of pH, temperature, or the concentration of metabolite and release their load as result of such a change. Fibers Glue Granules for holding soil moisture in arid areas Air bubble-repellent (superaerophobicity). Can improve the performance and stability of electrodes for water electrolysis. Culturing cells: Hydrogel-coated wells have been used for cell culture. Biosensors: Hydrogels that are responsive to specific molecules, such as glucose or antigens, can be used as biosensors, as well as in DDS. Cell carrier: Injectable hydrogels can be used to carry drugs or cells for applications in tissue regeneration or 3D bioprinting.
An exoskeleton is skeleton that covers the body of an animal, serving as armor to protect an animal from predators. Arthropods have exoskeletons that encase their bodies, and have to undergo periodic moulting or ecdysis as the animals grow. The shells of molluscs are another form of exoskeleton. Exoskeletons provide surfaces for the attachment of muscles, and specialized appendanges of the exoskeleton can assist with movement and defense. In arthropods, the exoskeleton also assists with sensory perception. An external skeleton can be quite heavy in relation to the overall mass of an animal, so on land, organisms that have an exoskeleton are mostly relatively small. Somewhat larger aquatic animals can support an exoskeleton because weight is less of a consideration underwater. The southern giant clam, a species of extremely large saltwater clam in the Pacific Ocean, has a shell that is massive in both size and weight. Syrinx aruanus is a species of sea snail with a very large shell.
Sources: en.wikipedia.org
==== Reclaimed water as feedstock ==== As semiconductor fabrication has scaled, the volume of feedwater required for ultrapure water production has grown substantially, with advanced fabrication plants consuming several million gallons of UPW per day. To reduce reliance on freshwater withdrawals, some manufacturers have begun using reclaimed municipal or industrial wastewater as raw feedstock for UPW production. Reclaimed water typically contains higher levels of small-molecule organic pollutants such as urea, which are not effectively removed by conventional ion exchange, reverse osmosis, or ultraviolet treatment. As a result, advanced oxidation processes (AOPs), including UV-AOP and sulfate-radical–based methods, have been investigated as supplementary unit operations to meet the increasingly stringent total organic carbon specifications required for sub-7 nm device fabrication.
Thirlby's Anderson was also highlighted, such as by Berkshire for carrying the film's emotional story and said, "one of the film's true thrills comes in watching Thirlby effortlessly balance the conflict between a Judge's merciless duties and a psychic's compassionate understanding." The New Statesman's Laura Sneddon noted that Dredd passed the Bechdel test, lacking in sexism or misogyny and positively portraying female characters who are no weaker, more sexualised or shown less than their male counterparts. Sneddon described Anderson as repeatedly shown to have power over men who underestimate her, while Ma-Ma displays more intelligence and sadism than any of her male gang members, and neither woman interacts with the other on the basis of their gender. Many US newspaper critics were less taken with the film. Mark Olsen of the Los Angeles Times called it "a clunk-headed action picture" that "simply becomes a monotonous series of bad-guy confrontations". Frank Lovece of Newsday described it as a "soullessly gritty" film, which apart from one believable scene involving Thirlby, is "all tough-guy talk and humorless cynicism". Stephen Whitty of The Star-Ledger called it a "gray and ugly film", said that there was little to draw viewers in, and wrote that apart from the drug-induced slow-motion sequences, the film offers nothing new.
== Specimen processing == For blood tests, clinical chemists must process the specimen to obtain plasma and serum before testing for targeted analytes. This is most easily done by centrifugation, which packs the denser blood cells and platelets to the bottom of the centrifuge tube, leaving the liquid serum fraction resting above the packed cells. This initial step before analysis has recently been included in instruments that operate on the "integrated system" principle. Plasma is obtained by centrifugation before clotting occurs.
== Degradation == Once secreted, GLP-1 is extremely susceptible to the catalytic activity of the proteolytic enzyme dipeptidyl peptidase-4 (DPP-4). Specifically, DPP-4 cleaves the peptide bond between Ala8-Glu9 resulting in the abundant GLP-1 (9–36) amide constituting 60–80% of total GLP-1 in circulation. DPP-4 is widely expressed in multiple tissues and cell types and exists in both a membrane-anchored and soluble circulating form. Notably, DPP-4 is expressed on the surface of endothelial cells, including those located directly adjacent to GLP-1 secretion sites. Consequently, less than 25% of secreted GLP-1 is estimated to leave the gut intact. Additionally, presumably due to the high concentration of DPP-4 found on hepatocytes, 40–50% of the remaining active GLP-1 is degraded across the liver. Thus, due to the activity of DPP-4 only 10–15% of secreted GLP-1 reaches circulation intact. Neutral endopeptidase 24.11 (NEP 24.11) is a membrane-bound zinc metallopeptidase widely expressed in several tissues, but found in particularly high concentrations in the kidneys, which is also identified accountable for the rapid degradation of GLP-1. It primarily cleaves peptides at the N-terminal side of aromatic or hydrophobic amino acids and is estimated to contribute by up to 50% to GLP-1 degradation. However, the activity only becomes apparent once the degradation of DPP-4 has been prevented, as the majority of GLP-1 reaching the kidneys has already been processed by DPP-4. Similarly, renal clearance appears more significant for the elimination of already inactivated GLP-1.
Sources: en.wikipedia.org
It is designed as a triple agonist acting on the GLP-1, GIP, and glucagon receptors. This combination is intended to influence appetite, insulin secretion, and energy expenditure. Single-receptor and dual-receptor compounds act on a narrower set of targets.
No. It remains investigational, and phase 3 results have not been fully published or reviewed by regulators. Official approval status should be confirmed through regulatory agencies rather than secondary sources.
The added glucagon receptor activity is the main difference in its mechanism. Whether that addition produces meaningful benefits in clinical outcomes is still being studied. Comparisons between compounds rest largely on indirect rather than head-to-head trial data.
意味着单个分子可同时结合三种代谢受体，而不是只作用于一种。其目的是整合食欲、胰岛素和能量消耗通路，但人体中的协同程度仍在研究。